Research brief / two receptors
Sermorelin vs Ipamorelin: GHRH Analog vs Ghrelin-Receptor Secretagogue
Same goal — more growth hormone — reached through two different doors on the pituitary.
The gist
Sermorelin vs ipamorelin comes down to which receptor each one presses. Sermorelin is a GHRH analog — it copies the brain's natural 'make growth hormone' signal and lands on the GHRH receptor. Ipamorelin is a GHRP (growth-hormone-releasing peptide) that works through a completely separate receptor, the ghrelin/GHS receptor. Same destination — a pulse of the body's own growth hormone — through two different doors. They are often discussed together because the two doors can be pressed at once, but they are not the same mechanism.
Sermorelin vs ipamorelin: what is the difference?
Sermorelin is a GHRH analog acting on the GHRH receptor (GHRH-R) on pituitary somatotrophs, via the cAMP/PKA pathway [7]. Ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the separate ghrelin/GHS receptor — a fundamentally different mechanism within the same GH-axis goal. So the difference is not potency or duration first; it is the door. Sermorelin uses the GHRH door; ipamorelin uses the ghrelin door.
GHRPs are a distinct secretagogue class from GHRH analogs [7]. That mechanistic separation is why the two are sometimes studied as complementary inputs — GHRH and ghrelin are two of the principal signals that converge on GH output [7].
Why the two receptors matter
The GHRH receptor and the ghrelin/GHS receptor are different proteins with different signaling, and the body uses both to shape growth-hormone release [7]. Sermorelin's appeal in the literature is that it copies the endogenous GHRH signal exactly — it is the native 1-29 fragment — so it works through the pathway the body already uses, with somatostatin and IGF-1 feedback intact [11]. Ipamorelin, on the ghrelin-receptor side, recruits a parallel input.
Neither is a brand-name drug; both are research peptides. For sermorelin specifically, the evidence base is the pediatric growth data [1], the adult GH/IGF-1 studies [2], and the pharmacokinetics [3] documented elsewhere on this site.
The feedback question — why "upstream" is the recurring word
Both compounds are upstream of growth hormone — neither supplies GH directly — but they sit at different upstream controls. Sermorelin presses the GHRH control, the same one the hypothalamus uses, so the pituitary's own brakes (somatostatin) and the IGF-1 feedback loop stay in the circuit [7][11]. That preserved feedback is why GHRH-route stimulation is described as supporting the natural pulsatile pattern rather than overriding it [11]. Ipamorelin's ghrelin-receptor input is a separate lever on the same machine. For a reader, the practical takeaway is conceptual, not prescriptive: a comparison between these two is a comparison of which physiologic lever each one pulls, and the sermorelin lever is the one with the documented pediatric and adult GH/IGF-1 record on this site [1][2].
Pharmacology: native pulse vs ghrelin-receptor recruitment
On the pharmacology, sermorelin's profile is the better-documented of the two. As native GHRH(1-29), it is rapidly cleared — a plasma half-life on the order of 10-12 minutes — yet a single dose elevates serum GH for roughly 3 hours [3], the brief physiologic pulse that defines its action. Its dose-response is characterized: intravenous GHRH(1-29) elicited GH release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg in healthy men [3].
Ipamorelin's appeal in the comparison is mechanistic rather than evidentiary here: it recruits the ghrelin/GHS receptor, a parallel and independent GH-stimulating input [7]. Because GHRH and ghrelin signals converge on the same somatotrophs through different receptors, the two doors are sometimes discussed as additive — but that is a statement about pathway architecture, not a head-to-head efficacy claim, and this site does not assert one beyond what the cited sermorelin studies show.
What sermorelin has that the comparison can't borrow
Two things are sermorelin-specific and don't transfer from the comparison. First, the regulatory history: sermorelin was a formerly FDA-approved prescription drug for pediatric GH deficiency (NDA 020443), withdrawn in 2008 for commercial reasons [4]. Second, the pediatric efficacy record: once-daily subcutaneous GHRH(1-29) roughly doubled first-year height velocity in GH-deficient children [1]. Those are GHRH-analog facts. The shared caution does transfer: both classes raise GH/IGF-1, so the theoretical-oncologic consideration and the WADA-prohibited status apply across the GH-secretagogue category [5]. For the full safety picture, see the sermorelin side effects page; for dosing context, the research doses of sermorelin.
How to read a sermorelin vs ipamorelin comparison honestly
The cleanest way to read sermorelin vs ipamorelin is to keep three things separate: mechanism, evidence, and marketing. On mechanism, they are genuinely different — GHRH receptor versus ghrelin/GHS receptor [7]. On evidence, sermorelin carries a documented pediatric-growth record [1] and characterized adult GH/IGF-1 and pharmacokinetic data [2][3], and this digest covers sermorelin's record, not a controlled trial pitting the two molecules against each other. On marketing, both are widely promoted for adult anti-aging benefits that outrun the rigorous data [5]. A comparison that respects all three avoids the common error of treating a difference in receptor as if it were a proven difference in outcome.
What this comparison is not
This page is a mechanistic and evidentiary comparison, not a buying guide and not a recommendation to combine or choose between research peptides. Both sermorelin and ipamorelin are laboratory research compounds here, not finished medicines, and nothing on this page is a dosing instruction. Where sermorelin has hard data — the pediatric height-velocity acceleration [1], the 14-day GH/IGF-1 reversal in older men [2], the characterized pharmacokinetics [3] — those findings are attributed to the specific studies that produced them. Where the comparison would require a head-to-head trial that hasn't been done, this page says so rather than inventing a verdict. The shared GH-secretagogue cautions — the theoretical-oncologic consideration and WADA prohibition [5] — apply to both, and are covered in full on the sermorelin side effects page.